Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Immune checkpoint inhibitors (ICIs) have improved outcomes in non-small cell lung cancer (NSCLC), yet treatment benefit remains heterogeneous and resistance is common. Genomic alterations, tumor microenvironment (TME) remodeling, and metabolic reprogramming across spatial and temporal scales that are incompletely captured by single-site tissue sampling.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
